We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in AVEO Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 110 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 110 → 0 (-110)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $368M → $0 (-$368M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 110

Holders
–
Holders Change
-110
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
110
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$22.6M
2
NAM
Nexpoint Asset Management
Texas
-$21.9M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$21.6M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$20.1M
5
Man Group
Man Group
United Kingdom
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
– -$4.72M -315,477 Closed
EFI
27
EHP Funds Inc
Canada
– -$4.37M -292,043 Closed
Geode Capital Management
28
Geode Capital Management
Massachusetts
– -$4.12M -275,892 Closed
GF
29
Gabelli Funds
New York
– -$3.93M -262,694 Closed
PCM
30
Pathway Capital Management
California
– -$3.67M -245,606 Closed
Tudor Investment Corp
31
Tudor Investment Corp
Connecticut
– -$3.37M -225,097 Closed
UBS Group
32
UBS Group
Switzerland
– -$2.89M -193,555 Closed
JP Morgan Chase
33
JP Morgan Chase
New York
– -$2.58M -172,658 Closed
WVP
34
Worth Venture Partners
New Jersey
– -$2.56M -170,925 Closed
DTL
35
Dynamic Technology Lab
Singapore
– -$2.41M -161,059 Closed
Two Sigma Advisers
36
Two Sigma Advisers
New York
– -$2.28M -152,600 Closed
GLAM
37
Gardner Lewis Asset Management
Pennsylvania
– -$2.18M -146,032 Closed
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
– -$2.11M -141,202 Closed
State Street
39
State Street
Massachusetts
– -$1.9M -127,282 Closed
TC
40
Trium Capital
United Kingdom
– -$1.83M -122,140 Closed
GI
41
GAMCO Investors
Connecticut
– -$1.81M -121,277 Closed
GCIA
42
Gabelli & Co Investment Advisers
New York
– -$1.78M -119,150 Closed
CANY
43
Caxton Associates (New York)
New York
– -$1.76M -117,452 Closed
Two Sigma Investments
44
Two Sigma Investments
New York
– -$1.61M -107,601 Closed
BGIM
45
Brandywine Global Investment Management
Pennsylvania
– -$1.58M -105,531 Closed
KC
46
Kellner Capital
New York
– -$1.5M -100,016 Closed
BC
47
Birchview Capital
Vermont
– -$1.5M -100,000 Closed
SAM
48
Silphium Asset Management
United Kingdom
– -$1.5M -100,000 Closed
Jane Street
49
Jane Street
New York
– -$1.21M -80,874 Closed
Swiss National Bank
50
Swiss National Bank
Switzerland
– -$1.12M -75,200 Closed
1
2
3 4 5

AVEO Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2023, worth a combined $0 — down 100% from $368M a quarter earlier.

Sellers outnumbered buyers: 110 funds closed out of AVEO and 0 opened new positions — a net loss of 110 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $22.6M sold.

  • 0 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2023, down from 110 in Q4 2022.
  • Funds reported $0 of AVEO Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2023 and 110 closed out, a net change of -110 holders.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2023 was Vanguard Group, an estimated $22.6M sold.

Based on aggregated 13F filings for Q1 2023.